NCT07135804View on ClinicalTrials.gov

Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2031

Conditions
Locally Advanced Nasopharyngeal Squamous Cell Carcinoma
Interventions
DRUG

Iparomlimab and Tuvonralimab Injection

Patients will receive Iparomlimab and Tuvonralimab Injection on the basis of 3 cycles of induction chemotherapy, followed by standard concurrent chemoradiotherapy, and then 9 cycles of Iparomlimab and Tuvonralimab Injection as adjuvant therapy

All Listed Sponsors
lead

Second Affiliated Hospital of Nanchang University

OTHER